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Application of New Cholesterol Guidelines to the Korean Adult 
Diabetic Patients
The American College of Cardiology and the American Heart Association (ACC/AHA) 2013 
joint guidelines for the treatment of hypercholesterolemia expand the indications for statin 
therapy. This study was performed to estimate the numbers of diabetic patients indicated 
for statin therapy according to the Third Adult Treatment Panel (ATP-III) of the National 
Cholesterol Education Program guidelines and the new ACC/AHA guidelines in Korea. We 
analyzed the data from the Korea National Health and Nutrition Examination Survey 
(KNHANES) 2010-2012. Patients with diabetes over 30 yr of age were analyzed by the two 
guidelines. Of the total 1,975 diabetic patients, only 377 (19.1%) were receiving drugs for 
dyslipidemia. Among 1,598 patients who had not taken any medications for dyslipidemia, 
65.6% would be indicated for statin therapy according to the ATP-III guidelines. When we 
apply the new guidelines, 94.3% would be eligible for statin therapy. Among the total 
diabetic patients, the new guidelines, compared with the ATP-III guidelines, increase the 
number eligible for statin therapy from 53.1% to 76.2%. The new guidelines would 
increase the indication for statin therapy for most diabetic patients. At present, many 
diabetic patients do not receive appropriate statin therapy. Therefore efforts should be 
made to develop the Korean guidelines and to ensure that more diabetic patients receive 
appropriate statin therapy.
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INTRODUCTION
Cardiovascular disease (CVD) is the major cause of morbidity 
and mortality in patients with diabetes. Dyslipidemia, a com-
mon condition coexisting with type 2 diabetes, is a major cause 
of atherosclerosis and a risk factor for CVD. Numerous studies 
have shown that lowering lipid levels is very important for pre-
venting CVD in patients with diabetes (1,2).
 Since their release, the guidelines of the Third Adult Treat-
ment Panel (ATP-III) of the National Cholesterol Education Pro-
gram have been used globally in the treatment of hyperlipid-
emia (3,4). The ATP-III guidelines defined patients with diabe-
tes as coronary heart disease equivalent condition and high risk 
of CVD group. Individuals at high risk with low-density lipopro-
tein cholesterol (LDL-C) levels ≥ 100 mg/dL are candidates for 
statin therapy. The ATP-III guidelines calculated the 10-yr risk 
of coronary heart disease (CHD) using the Framingham risk 
calculator (5).
 The American College of Cardiology and the American Heart 
Association (ACC/AHA) guidelines for the management of cho-
lesterol were released in November 2013 (6). The new guide-
lines expand the recommendation for statin therapy to all pa-
tients with diabetes aged 40-75 yr with LDL-C levels ≥ 70 mg/dL 
who also have a 10-yr risk of CVD ≥ 7.5%, as estimated based 
on new pooled cohort equations (7).
 In Korea, the prevalence rate of dyslipidemia increased from 
1998 to 2010, but the treatment rate of diabetic patients in 2010 
was only 23.6% (8). This study used data from the Korea Nation-
al Health and Nutrition Examination Surveys (KNHANES) to 
estimate the number of patients with diabetes in Korea for whom 
statin therapy would be recommended based on the new guide-
lines compared with the ATP-III guidelines.
MATERIALS AND METHODS
Study population
This study was performed using data from the KNHANES V (2010-
2012) conducted by the Division of Health and Nutritional Sur-
vey under the Korean Centers for Disease Control and Preven-
tion (KCDCP). This is a nationwide, community-based cross-
sectional survey examining the general health and nutrition 
status of the civilians of Korea. Participants were selected from 
sampling units based on geographical area, sex, and age group 
using household registries and a stratified, multistage, clustered, 
probability sampling design. This sampling method is certified 
to produce representative statistics by the Korea National Sta-
ORIGINAL ARTICLE
Endocrinology, Nutrition & Metabolism
Kim BK, et al. • New Cholesterol Guidelines for Diabetes 
http://jkms.org  1613http://dx.doi.org/10.3346/jkms.2015.30.11.1612
tistical Office. 
 The diagnostic criteria for diabetes were taken from the Amer-
ican Diabetes Association (ADA) guidelines (9). Patients over 
30 yr of age were defined as having diabetes if they had already 
been diagnosed as diabetic by a physician or had a fasting plas-
ma glucose level ≥ 126 mg/dL or HbA1c level ≥ 6.5%. We ex-
cluded participants who fasted less than 8 hr before blood sam-
pling and who had missing LDL-C level data. After these exclu-
sions, a total of 1,975 patients with diabetes for whom LDL-C 
levels that were directly measured or calculated by Friedewald’s 
equation were available (10).
 The diabetic patients were divided into dyslipidemia treat-
ment versus non-treatment groups. The patients in the dyslip-
idemia treatment group were defined as those who reported 
taking medications for dyslipidemia. Treatment for dyslipid-
emia was not limited to statins but included any type of drug. 
We assessed the eligibility for statin therapy using the 2004 up-
dated ATP-III criteria as well as the 2013 ACC/AHA guidelines. 
According to the ATP-III guidelines, patients with diabetes should 
be considered at high risk. Statin therapy is recommended in 
high-risk patients with a LDL-C level ≥ 100 mg/dL. The new 
ACC/AHA guidelines recommend moderate-intensity statin 
therapy in all diabetic patients between the ages of 40 and 75 yr 
and moderate-to-high-intensity statin therapy in those with a 
10-yr risk of CVD ≥ 7.5%.
Biochemical measurements
After fasting for 8 hr or more, blood samples were drawn from 
the antecubital vein of each participant in the morning. Sam-
ples were processed appropriately, refrigerated at 2-8°C, and 
transported to the Central Testing Institute, Seoul, Korea. After 
transport, plasma was separated by centrifugation and analyzed 
within 24 hr.
 The fasting plasma concentrations of glucose and lipid were 
measured using a Hitachi Automatic Analyzer 7600 (Hitachi, 
Tokyo, Japan). High-performance liquid chromatography (HLC-
723G7; Tosoh, Tokyo, Japan) was used to measure HbA1c. 
 The HDL-C level was calculated according to the Lipid Stan-
dardization Program of the US Centers for Disease Control and 
Prevention (CDC). The formula used in 2012 was different from 
that in 2010-2011. LDL-C levels have been measured directly 
using automated enzymatic techniques since 2009 in KNHANES 
IV. LDL-C levels were calculated using Friedewald’s formula (11) 
in subjects with no direct LDL data. 
Statistical analysis
All statistical analyses in this study were performed using weight-
ed variables with stratification and clustering variables to incor-
porate sample weights and to adjust for the complex sample 
design of the survey. Nominal variables are presented as the 
numbers of cases and percentages, and continuous variables 
are presented as means ± standard deviations. We compared 
the baseline characteristics of men and women by Student’s t-
test and chi-square test. We determined the proportion of the 
patients with diabetes in KNHANES for whom statin therapy 
would be recommended on the basis of the two guidelines. 
 We calculated the new ACC/AHA pooled-cohort equations 
to determine the proportions of adults with a 10-yr risk of CVD 
≥ 7.5%. All analyses were conducted using SPSS version 19.0 
software (IBM, Chicago, IL, USA).
Table 1. Comparison of baseline characteristics between men and women among Korean adult diabetic patients
Parameters
Total 
n = 1,975
Men
n = 1,010
Women
n = 965
P value
Age (yr) 62.64 ± 11.42 61.24 ± 11.23 64.11 ± 11.44 < 0.001
Height (cm) 160.56 ± 9.27 167.27 ± 6.23 153.55 ± 6.26 < 0.001
Weight (kg) 64.87 ± 11.49 68.86 ± 10.58 60.70 ± 10.91 < 0.001
BMI (kg/m2) 25.09 ± 3.53 24.54 ± 2.98 25.67 ± 3.95 < 0.001
Waist circumference (cm) 87.43 ± 9.35 87.92 ± 8.64 86.92 ± 10.02 0.019
Systolic BP (mmHg) 128.81 ± 17.03 127.57 ± 16.51 130.11 ± 17.46 0.001
Diastolic BP (mm Hg) 76.38 ± 10.53 77.64 ± 10.74 75.07 ± 10.14 < 0.001
Fasting plasma glucose (mg/dL) 138.13 ± 42.52 140.69 ± 41.85 135.44 ± 41.02 0.005
HbA1c (%) 7.32 ± 1.40 7.32 ± 1.43 7.32 ± 1.37 0.996
Total cholesterol (mg/dL) 187.78 ± 41.30 182.61 ± 39.80 193.20 ± 42.16 < 0.001
HDL cholesterol (mg/dL) 44.49 ± 10.71 43.32 ± 10.15 45.70 ± 11.13 < 0.001
LDL cholesterol (mg/dL) 112.05 ± 35.80 108.65 ± 35.07 115.61 ± 36.22 < 0.001
Triglyceride (mg/dL) 173.93 ± 131.43 183.21 ± 142.96 164.22 ± 39.03 0.001
Treatment of hyperlipidemia
   Yes
   No
146 (14.5%)
864 (85.5%)
231 (23.9%)
734 (76.1%)
< 0.001
Smoking
   Yes
   No
377 (37.3%)
633 (62.7%)
51 (5.3%)
915 (94.7%)
< 0.001
BP, blood pressure.
Kim BK, et al. • New Cholesterol Guidelines for Diabetes 
1614  http://jkms.org http://dx.doi.org/10.3346/jkms.2015.30.11.1612
Ethics statement
The survey was approved by the institutional review board of 
KCDCP (approval numbers 2010-02CON-21-C, 2011-02CON-
06-C, and 2012-01EXP-01-2C). All participants provided inform-
ed consent.
RESULTS
A total of 25,534 individuals participated in the health interview 
and examination in KNHANES V in 2010-2012. Of these, 17,292 
subjects were ≥ 30 yr of age, among whom 12.5% (2,165 pati-
ents) had diabetes. A total of 190 participants was excluded be-
cause of missing LDL-C data, leaving 1,975 patients (aged 62.64 
± 11.42 yr, 30-90 yr) with diabetes analyzed in this study. Table 1 
shows a comparison of the baseline characteristics between 
men and women. There was no difference in HbA1c levels be-
tween men and women (7.3 vs. 7.3, respectively, P = 0.996). Wo-
men were older than men (64.11 vs. 61.24, respectively, P < 0.001) 
and had higher levels of total cholesterol and LDL-C (193.2 vs. 
182.61, respectively, P < 0.001; 115.61 vs. 108.65, respectively, 
P < 0.001). A larger proportion of female patients (23.9%) than 
male patients (14.5%) had been taking medications for dyslip-
idemia.
 Fig. 1 shows the flow of the process used to determine the fi-
nal subjects selected for analysis according to the two sets of 
guidelines for the management of cholesterol. Among the 1,598 
diabetic patients who had never taken medications for dyslip-
idemia, 1,048 patients (65.6%) were recommended for statin 
therapy according to the NCEP/ATP-III guidelines. According 
to the new ACC/AHA guidelines, 94.3% (72.8% required mod-
erate-to-high-intensity therapy; 21.5% required moderate-in-
tensity therapy) were recommended for statin therapy. 
 Among the 1,975 Korean adult diabetic patients, 19.1% (n =  
377) had already been taking drugs for dyslipidemia. If patients 
with LDL levels > 130 mg/dL were recommended for statin 
therapy, an additional 25.3% (n = 500) would be classified as 
requiring statin therapy. After application of the NCEP/ATP-III 
guidelines, an additional 53.1% (n = 1,048) were classified as 
requiring statin therapy. Application of the new ACC/AHA gui-
delines resulted in an indication for statin therapy in an addi-
tional 76.2% of patients (n = 1,506) (Fig. 2).
 Among the 1,598 patients not taking any drugs for dyslipid-
25,534 individuals participated in health interview and examination in the fifth 
KNHANES in 2010-2012
17,292 participants were aged more than 30 yr
Exclude 190 participants who had missing data with  
   respect to LDL cholesterol. 
19.1%  (377 individuals) had been taking medicines for  
   dyslipidemia
Among them, 12.5% (2,165 individuals) had been having diabetes 
 A total 1,975 patients with diabetes who had LDL cholesterol level 
1,598 diabetic patients were analyzed finally
NCEP/ATPIII, 2004 ACC/AHA, 2013
1,048 patients (65.6%) would be 
recommended statin therapy
(LDL cholesterol ≥ 100 mg/dL) 
1,163 (72.8%) would be 
recommended moderate-high 
intensive statin therapy 
(ASCVD ≥ 7.5%)
Among 435 patients, 343 patients 
(21.5%) would be recommeded 
moderate intensive statin therapy
(40 ≤ aged ≤ 75)
Diagnostic criteria of diabetes
   a. Previous history of diagnosed diabetes by physician or
   b. Fasting plasma glucose ≥ 126 mg/dL or
   c. HbA1c ≥ 6.5%
Fig. 1. Extrapolation of the KNHANES sample to adults with diabetes, according to two sets of guidelines for the management of cholesterol. KNHANES, Korea National Health 
and Nutrition Examination Survey; LDL, Low-density lipoproterin; NCEP, National Cholesterol Education Program; ATP III, Third Adult Treatment Panel; ACC/AHA, American Col-
lege of Cardiology and the American Heart Association; ASCVD, arteriosclerotic cardiovascular disease. 
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Fig. 2. Percentage of Korean adult diabetic patients, among 1975 total diabetic pa-
tients, indicated for statin therapy according to the guidelines. NCEP, National Choles-
terol Education Program; ATP III, Third Adult Treatment Panel; ACC/AHA, American 
College of Cardiology and the American Heart Association.
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Fig. 3. Percentage of Korean adult diabetic patients, among 1598 patients currently 
not taking antihyperlipidemic drugs, indicated for statin therapy according to the 
guidelines. (A) According to sex. (B) According to age. 
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emia, according to the NCEP/ATP-III guidelines, more female 
patients and those aged < 60 yr required statin treatment than 
did male patients and those aged ≥ 60 aged (69.7% vs. 62%, re-
spectively; 68.7% vs. 63.6%, respectively). On the other hand, 
according to the ACC/AHA guidelines, more patients required 
statin treatment among males and those aged ≥ 60 yr than did 
females and patients aged < 60 yr (94.5% vs. 93.8%, respective-
ly; and 97% vs. 89.9%, respectively) (Fig. 3).
DISCUSSION
Over the past two decades, many randomized controlled trials 
have shown that lowering LDL-C levels with statin therapy re-
duces the incidence of atherosclerotic CVD under clinical con-
ditions (12,13). The new ACC/AHA cholesterol guidelines were 
developed based on this evidence and emphasize primary pre-
vention of cardiovascular disease. In diabetic patients, the new 
guidelines suggest that most patients require statin therapy. The 
2015 ADA guidelines accept this concept of statin therapy for 
primary prevention in diabetic patients (14). We estimated the 
percentage of Korean adult diabetic patients requiring statin ther-
apy according to the two sets of guidelines using the KNHANES 
data. 
 In this study, female Korean diabetic patients had higher lev-
els of total cholesterol and LDL-C despite the larger portion tak-
ing drugs for dyslipidemia. As the mean age of women was old-
er than that of men, it is possible that the group of women in-
cluded a larger number of those older than 50 yr. According to a 
previous study, in the Korean general population, men had more 
hypercholesterolemia and hyper-LDL-cholesterolemia among 
the younger aged population (< 50 yr), whereas among those of 
older age (≥ 50 yr), women had more hypercholesterolemia and 
hyper-LDL-cholesterolemia. Women had higher HDL-C levels 
in all age groups (8). The same difference in HDL-C level was 
also found in American national data (15,16). In this study, Ko-
rean diabetic patients showed no differences in HDL levels be-
tween men and women. This may have been because diabetic 
patient have low levels of HDL-C. 
 We estimate that under the new guidelines, 94.3% of diabetic 
patients will be indicated for statin therapy, representing almost 
all patients with diabetes. This population would represent an 
increase of 28.7% over the number currently eligible according 
to the ATP-III guidelines (65.6%). These new treatment recom-
mendations have a larger effect in older aged (≥ 60 yr) than youn-
ger aged individuals (< 60 yr) and in men than women (Fig. 3). 
These trends are similar to those in the general population in 
the USA (17). The differences according to age may be partially 
explained by the new pooled-cohort equations (7). The new 
equation targeted prevention of stroke and coronary heart dis-
ease, as the prevalence of CVD rises markedly with age (18). In 
the Korean population, approximately 90% of old people require 
statins for primary prevention according to the new guidelines 
(19). However, there are few data showing the benefit of statin 
treatment in older people without CVD (20). Instead, younger 
individuals were shown to require more aggressive preventive 
treatment for CVD. The new guidelines would also result in more 
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men being newly indicated for statin therapy than women, al-
though women had worse dyslipidemia. This may be explained 
by the new guidelines also expanding the indication for statin 
therapy among adults with other risk factors for CVD, even at low-
er levels of LDL-C. More male than female patients are smokers.
 The purpose of treatment of dyslipidemia is not simply nor-
malization of cholesterol level itself, but also the prevention of 
CVD and a decrease in mortality rate. Diabetes is a serious risk 
factor for CVD. Therefore, the ADA recommended statin thera-
py for all patients with diabetes aged > 40 yr without additional 
CVD risk factors, with consideration of moderate-intensity statins 
for primary prevention (14). However, it remains unclear wheth-
er Asian diabetic patients should follow these guidelines. The 
Japan Atherosclerosis Society (JAS) recommends a goal of LDL-
C level < 120 mg/dL for the high-risk group as well as diabetes 
for primary prevention (21). These recommendations are based 
on Japanese epidemiological studies (22-24). These studies in-
dicated that low-dose statins are effective for prevention of ath-
erosclerotic CVD (ASCVD) in Japanese patients. Several studies 
showed that relatively low-dose statins had a high lipid-lower-
ing effect in Korean subjects (25-27). According to the new gui-
delines, high-intensity statins are a taken at a daily dose that 
lowers LDL-C by an average of approximately ≥ 50%, e.g., ator-
vastatin 40-80 mg or rosuvastatin 20-40 mg. Moderate-intensity 
statins are taken at a daily dose that lowers LDL-C by 30%-50%, 
such as atorvastatin 10-20 mg or rosuvastatin 5-10 mg. A clini-
cal study in Korea showed that atorvastatin at 10 mg decreased 
LDL-C levels by 41.8% from baseline, and a decrease of 48.8% 
was observed with only 5 mg rosuvastatin. In another Korean 
study, there were no differences in major adverse cardiac events 
between high-intensity and low-to-moderate-intensity statin 
therapy in patients with acute myocardial infarction (26). There-
fore, it may be possible for Korea to reach the same goal of CVD 
prevention as the new guidelines but with relatively lower doses 
of statin. However, it is still controversial as to which statins and 
doses are most effective, as the Korean absolute CVD risk is low-
er than those in Western countries, and there are insufficient 
long-term data. Even among Asian ethnic differences in cardio-
vascular mortality (28), respective countries need their own gui-
delines for prevention of ASCVD.
 Nevertheless, Korean diabetic patients have not received ap-
propriate management for dyslipidemia. We showed that only 
19.1% of diabetic patients were taking antidyslipidemic medi-
cations. As these medications include any drugs for dyslipid-
emia, the real proportion of patients taking statin may be small-
er than 19%. If we assume the goal is to lower LDL-C levels to 
< 130 mg/dL, an additional 25.3% of patients need statin thera-
py. This level is higher than the JAS guidelines for diabetic pa-
tients. Even according to the ATP-III guidelines, an additional 
53.1% of patients require statin treatment. At present, the Kore-
an national health insurance system guarantees statin therapy 
in cases with LDL-C levels > 100 mg/dL. Therefore, more than 
half of all diabetic patients in Korea have not received statin ther-
apy. It is necessary to at least ensure that diabetic patients are 
managed according to the proper guidelines.
 This is the first study regarding application of the new choles-
terol guidelines to Korean diabetic patients. We used validated 
national data from KNHANES V (2010-2012). However, we did 
not consider peripheral vascular disease or previous cardiovas-
cular events and did not predict real effects of the new and old 
guidelines on diabetic patients due to a lack of Korean cohort 
data.
 In conclusion, the new ACC/AHA guidelines would increase 
the indication for statin therapy of most diabetic patients. The 
issues involved with application of the new guidelines to the 
Korean diabetic population should be discussed further in fu-
ture studies. At present, many diabetic patients do not receive 
appropriate statin therapy. Efforts should be made to ensure 
that more diabetic patients receive appropriate statin therapy 
and to develop the Korean guidelines.
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